Topical application of a cyclic GMP analog lowers IOP in normal and ocular hypertensive rabbits.
OBJECTIVE
To determine whether a new cyclic GMP analog, 2'-O-(4-benzoyl)benzoylguanosine 3',5' cyclic monophosphate (BB-cGMP), significantly reduces intraocular pressure in either normotensive or hypertensive eyes of rabbits.


METHODS
Intraocular pressure of normal adult rabbits and/or rabbits with alpha-chymotrypsin-induced ocular hypertension was measured after topical application of BB-cGMP for up to 72 hours after treatment.


RESULTS
Data indicate that topical application of solutions containing BB-cGMP can significantly reduce intraocular pressure in normotensive eyes and, to a greater extent, hypertensive eyes for periods up to 12 hours for a single dose.


CONCLUSIONS
BB-cGMP holds interest both as a clinical agent in the management of intraocular pressure and for in vitro biochemical studies on the regulation of intraocular pressure.
Stein
P J
PJ
Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut.
Clack
J W
JW
D000287:Administration, Topical; D000818:Animals; D002918:Chymotrypsin; D006152:Cyclic GMP / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D007429:Intraocular Pressure / Q000187:drug effects*; D009798:Ocular Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000138:chemical synthesis / Q000494:pharmacology*; D011817:Rabbits; D014065:Tonometry, Ocular
D009883:Ophthalmic Solutions; D010726:Phosphodiesterase Inhibitors; C088792:2'-O-(4-benzoylbenzoyl)guanosine cyclic 3',5'-monophosphate; D002918:Chymotrypsin; D006152:Cyclic GMP